Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

This study is testing RYZ101, a targeted radioactive drug that seeks out tumors expressing a protein called SSTR (somatostatin receptor), in combination with standard chemotherapy for people with extensive-stage small cell lung cancer (SCLC). SCLC is an aggressive lung cancer, and new approaches are urgently needed. **You may be eligible if...** - You are 18 years or older - You have confirmed extensive-stage small cell lung cancer (meaning it has spread beyond one lung) - You are untreated or have only received up to 1 cycle of standard chemotherapy - You are a candidate for standard platinum-etoposide chemotherapy plus a PD-L1 immunotherapy drug **You may NOT be eligible if...** - Your tumor does not express the SSTR receptor (tested by imaging or biopsy) - You have other conditions that make combination therapy unsafe Talk to your doctor to see if this trial is right for you.